Synapse - Michael Morris

Results (586)

Prognostic value of neutrophil-to-lymphocyte ratio and lymphopenia in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with [177Lu]Lu-PSMA-617: VISION post hoc analysis

Meeting Abstract

Wei, X. X.; Chi, K. N. N.; de Bono, J. S.; Fizazi, K.; Krause, B.; Herrmann, K.; Rahbar, K.; Tagawa, S. T.; Morris, M. J.; Meisel, A.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer

Meeting Abstract

Morris, M. J.; Armstrong, A. J.; Chi, K. N. N.; de Bono, J. S.; Herrmann, K.; Krause, B.; Rahbar, K.; Sartor, O.; Tagawa, S. T.; Nagarajah, J.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Evaluating immune-related adverse events using PRO-CTCAE in a phase II study of ipilimumab for hormone-sensitive prostate cancer

Journal Article

Vargas P. de Almeida, D.; Anderson, J. M.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Cohn, E. D.; Baser, R. E.; Scher, H. I.; Autio, K. A.
Journal of Immunotherapy and Precision Oncology (2023)

Fulltext@MSK | Save

Association of baseline quantitative [68Ga]Ga-PSMA-11 PET imaging parameters with clinical outcomes in patients with mCRPC receiving [177Lu]Lu-PSMA-617: a VISION sub-study

Meeting Abstract

Kuo, P. H.; Morris, M.; Kendi, A. T.; Rahbar, K.; Wei, X. X.; Fang, B.; Armstrong, A. J.; Hesterman, J.; Chi, K.; de Bono, J.; more...
European Journal of Nuclear Medicine and Molecular Imaging (2023)

Fulltext@MSK | Save

A phase 1, open-label, dose-ascending study to evaluate the safety and tolerability of the therapeutic radiopharmaceutical (131)I-MIP-1095 for the treatment of metastatic castration-resistant prostate cancer

Journal Article

Laccetti, A. L.; Bodei, L.; O'Donoghue, J. A.; Weber, W. A.; Morris, M. J.
Clinical Nuclear Medicine (2023)

Fulltext@MSK | Save

A pilot study of stereotactic body radiotherapy and (177)Lu-PSMA-617 for oligometastatic hormone sensitive prostate cancer

Meeting Abstract

Imber, B. S.; Bodei, L.; Humm, J.; Ionescu, A.; Wu, W.; Grkovski, M.; O'Donoghue, J.; Reddy, R. P.; Rimner, A.; Shasha, D.; more...
International Journal of Radiation Oncology, Biology, Physics (2023)

Fulltext@MSK | Save

SNMMI consensus statement on patient selection and appropriate use of (177)Lu-PSMA-617 radionuclide therapy

Guidelines

Hope, T. A.; Antonarakis, E. S.; Bodei, L.; Calais, J.; Iravani, A.; Jacene, H.; Koo, P. J.; Morgans, A. K.; Osborne, J. R.; Tagawa, S. T.; more...
Journal of Nuclear Medicine (2023)

Fulltext@MSK | Save

PSMAddition: A phase 3 trial to compare treatment with (177)Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer

Meeting Abstract

Tagawa, S. T.; Sartor, A. O.; Saad, F.; Reid, A. H.; Sakharova, O. V.; Feng, F. Y.; Fizazi, K.; Morris, M. J.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001)

Meeting Abstract

Gupta, S.; Ballman, K. V.; Galsky, M. D.; Morris, M. J.; Sridhar, S. S.; Chen, R. C.; Chan, T. A.; Wen, Y.; Grivas, P.; Tan, A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC)

Meeting Abstract

Halabi, S.; Guo, S. S.; Roy, A.; Rydzewska, L.; Godolphin, P.; Hussain, M. H. A.; Tangen, C.; Thompson, I.; Xie, W.; Carducci, M. A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save